Image-guided radiation therapy vendor ViewRay's MRIdian MRI-guided radiation therapy system now can be sold and used in China.
The Chinese regulatory authority, the National Medical Products Administration (NMPA), approved the system, which allows ViewRay to expand its global reach.
The MRIdian stereotactic MRI-guided adaptive radiotherapy (SMART) enables treatment that integrates diagnostic-quality MRI scans, on-table adaptive replanning, and continuous, real-time, soft-tissue tracking and automated beam gating.
Additionally, the system provides oncologists anatomical visualization through MRI scans and the ability to adapt a radiation therapy plan to the targeted cancer with a patient on the table. Doctors can define tight treatment margins to avoid unnecessary radiation exposure to organs and healthy tissue, and it allows the delivery of ablative radiation doses in five or fewer treatment sessions without relying on implanted markers.
